JP2003512421A5 - - Google Patents

Download PDF

Info

Publication number
JP2003512421A5
JP2003512421A5 JP2001532749A JP2001532749A JP2003512421A5 JP 2003512421 A5 JP2003512421 A5 JP 2003512421A5 JP 2001532749 A JP2001532749 A JP 2001532749A JP 2001532749 A JP2001532749 A JP 2001532749A JP 2003512421 A5 JP2003512421 A5 JP 2003512421A5
Authority
JP
Japan
Prior art keywords
bms
pyrimidin
hydroxymethyl
cis
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001532749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003512421A (ja
Filing date
Publication date
Priority claimed from US09/429,863 external-priority patent/US6432966B2/en
Application filed filed Critical
Publication of JP2003512421A publication Critical patent/JP2003512421A/ja
Publication of JP2003512421A5 publication Critical patent/JP2003512421A5/ja
Pending legal-status Critical Current

Links

JP2001532749A 1999-10-29 2000-10-27 抗ウィルス複合薬 Pending JP2003512421A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/429,863 1999-10-29
US09/429,863 US6432966B2 (en) 1999-10-29 1999-10-29 Antiviral combinations
PCT/GB2000/004137 WO2001030329A2 (en) 1999-10-29 2000-10-27 Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction

Publications (2)

Publication Number Publication Date
JP2003512421A JP2003512421A (ja) 2003-04-02
JP2003512421A5 true JP2003512421A5 (https=) 2007-12-20

Family

ID=23705033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001532749A Pending JP2003512421A (ja) 1999-10-29 2000-10-27 抗ウィルス複合薬

Country Status (10)

Country Link
US (1) US6432966B2 (https=)
EP (1) EP1225904B1 (https=)
JP (1) JP2003512421A (https=)
AR (1) AR026255A1 (https=)
AT (1) ATE273012T1 (https=)
AU (1) AU1042701A (https=)
DE (1) DE60012961T2 (https=)
ES (1) ES2225245T3 (https=)
TW (1) TWI282735B (https=)
WO (1) WO2001030329A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20053504B (en) * 2000-02-29 2005-05-10 Bristol Myers Squibb Co Low Dose Entecavir Pharmaceutical Composition and Use Thereof for Treatment of Hepatitis B
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US8168568B1 (en) * 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1抗原決定位胜肽及含此胜肽的疫苗
CN102552210B (zh) * 2012-01-10 2013-12-11 四川海思科制药有限公司 一种恩替卡韦胶囊组合物及其制备方法
KR20170132327A (ko) * 2015-04-07 2017-12-01 스프링 뱅크 파마슈티칼스, 인크. Hbv 감염의 치료를 위한 조성물 및 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800452D0 (sv) * 1998-02-13 1998-02-13 Medivir Ab Antivirals
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5206244A (en) 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
WO1992020344A1 (en) 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
WO1998046241A1 (en) * 1997-04-15 1998-10-22 Advanced Viral Research Corp. A combination therapy for hiv infections
CA2309357A1 (en) * 1997-09-25 1999-04-01 Bud C. Tennant Method for inhibiting development of liver cancer and increasing survival in chronic hepadnavirus infection

Similar Documents

Publication Publication Date Title
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ES2374117T3 (es) Componente de silibinina para el tratamiento de la hepatitis.
JP2002528502A5 (https=)
CA2066403A1 (en) Transmucosal dosage form
BG106906A (bg) Пуринови производни
JP2004509061A5 (https=)
WO1997006804A1 (en) 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c
CA2682254A1 (en) 1,3-oxathiolane nucleoside analogues
JP2005515966A5 (https=)
WO2003045437A8 (en) Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
WO2006017505A3 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
JP2005508963A5 (https=)
JP2009517411A5 (https=)
CN101563071A (zh) 尼古丁经口粘膜剂型
JP2003512421A5 (https=)
JP2002540148A5 (https=)
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
JP2002326936A5 (https=)
WO2005048978A3 (en) A controlled release pharmaceutical composition and a process for preparing the same
AR030551A1 (es) Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante
JP2003523385A5 (https=)
RU2003106417A (ru) Применение комбинации витаминов для лечения первичных головных болей
JP2008520672A (ja) チプラナビルとダルナビルの共投与によるhiv感染症の治療方法
WO2004002498A1 (en) Antiviral regimens